- $88.40m
- -$4.45m
- $0.86m
Brief: Rallybio Announces Positive Preliminary Results For Rlyb212, An Anti-HPA-1A Monoclonal Antibody For The Prevention Of Fetal And Neonatal Alloimmune Thrombocytopenia
Brief: Rallybio Corp - Files For Mixed Shelf Offering Of Up To $300 Million - SEC Filing
Brief: Rallybio Corp - Phase 1 Study Of Rlyb116 Ongoing Initial Single Dose Safety, PK, And PD Data Expected For 30 Mg Dose In 4Q 2022
Brief: Rallybio Corp - On August 1, 2022 Board Increased Its Size From Nine Directors To Ten Directors
Brief: Rallybio - Fryer Will Continue To Serve As Co's CFO Until A New CFO Has Been Appointed And Will Retire From Company Following A Transition Period
Brief: Rallybio Reports First Quarter Net Loss Per Common Share Of $0.48
Brief: Rallybio Announces In-Licensing Of Potential First-In-Class Preclinical Antibody Candidate From Sanofi
Brief: Rallybio Reports Fourth Quarter And Full Year 2021 Financial Results
NASDAQ RESUMED AT 09:41 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:35 AM
Brief: Rallybio Reports Positive Data In Clinical Program For Prevention Of FNAIT
Brief: Rallybio Corporation Reports Third Quarter 2021 Financial Results And Recent Business Highlights
Brief: Rallybio Corp Posts Q2 Loss Per Share $2.80